Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OXL001, has been developed utilising a novel bio-enabling platform technology, it has been taken into clinical studies which gives its immense potential as a pan-cancer therapy.
Lead Product(s): OXL001
Therapeutic Area: Oncology Product Name: OXL001
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Quotient Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2022
Details:
Oxilio has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) for its first Clinical Trial Application (CTA) with OXL001.
Lead Product(s): OXL001
Therapeutic Area: Oncology Product Name: OXL001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quotient Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2022